Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines
CANNANNEW REPORT

Internationally Recognized Neuroscience Experts Will Work Closely with Enveric Scientists to Help Drive Clinical Innovation and Success CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced the formation of its Scientific Advisory Board (SAB) comprised of science and technology leaders, including globally renowned CNS and mental disorders experts, and chaired by Maurizio Fava, M.D. The SAB will advise Enveric on the Company’s technology capabilities, innovation pipeline, early-stage candidate prioritization, and partnering opportunities. Additionally, the SAB will provide insights on emerging trends in neuroscience and technology, as well as the potential implications for advancing the Company’s pipeline of psychedelic-inspired new drug candidates for patients suffering from mental health diseases. “I am delighted to announce Enveric’s new Scientific Advisory Board comprised of leading experts in the field of CNS drug development. We are honored to have these remarkable and accomplished scientific leaders join our SAB during this time of scientific innovation to create new medicines for mental health indications with high unmet needs,” said Bob Dagher, M.D., Chief Medical Officer of Enveric. “These world-renowned experts have made significant contributions and pioneered breakthroughs in psychiatric research and therapeutics, and collectively, they bring a wealth of knowledge and experience for Enveric, as we work to develop our proprietary psychedelic-inspired therapies to treat CNS diseases.” The founding members of the Enveric Scientific Advisory Board for Mental Health Indications are: Maurizio Fava, M.D. Dr. Maurizio Fava is Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), executive director of the Clinical Trials Network and Institute, (MGH), associate dean for clinical and translational research, and the Slater Family Professor of Psychiatry at Harvard Medical School. Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored…

Excerpt only …
READ MORE BELOW
Source : Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.